Between now and 2030, close to 100 biologics in the US are set to lose exclusivity, representing $120 billion in sales the year before expiration. This shift presents an sizeable opportunity for the biosimilars market, which has yet to fully capture its potential.
The upcoming years will offer numerous learning opportunities for both originator and biosimilar manufacturers shaping the future trajectory of the industry.
In this article, Evaluate explores the opportunities ahead and discusses how factors like defensive strategies, biosimilar contracting, and the Inflation Reduction Act (IRA) will influence market dynamics.
Why read this article?
Get data-driven insights on:
- Blockbuster drugs nearing their patent cliff
- Therapy areas attracting biosimilar developers
- Defensive strategies originators may employ
- Key considerations for pricing biosimilars
- How to factor the IRA into strategic planning
